Boehringer Ingelheim’s Spevigo (spesolimab) Receives EC’s Conditional Marketing Authorization for Generalized Pustular Psoriasis Flares
Shots:
- The EC has granted conditional marketing authorization for spesolimab to treat adults patients with GPP flares
- The EC’s conditional approval was based on the P-II trial (EFFISAYIL 1) results of spesolimab vs PBO which showed that patients experienced a GPP flare @12wk., 54% vs 6% showed no visible pustules & AEs (66% vs 56%) after 1wk., infections were reported (17% vs 6%) & SAEs were reported in 6%
- Spesolimab is a novel selective Ab that blocks the activation of the interleukin-36 receptor & is already approved in the US & Japan for GPP. The therapy is also under investigation for the prevention of GPP flares & for other neutrophilic skin diseases
Ref: Businesswire | Image: Boehringer Ingelheim
Related News:- Boehringer Ingelheim’s Spevigo Receives the US FDA’s Approval as the First Treatment Option for Generalized Pustular Psoriasis Flares
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
